ALKERMES | ALKS - Loan Capital


ALKERMES reported $1.48B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Acadia Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 1.48B 1.2B Mar/2026
Amgen USD 51.89B 1.88B Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
J&J USD 37.53B 1.91B Mar/2026
Malin Corporation EUR 0 0 Dec/2024
Merck USD 46.67B 77M Mar/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Otsuka Holdings JPY 164.96B 1.96B Mar/2026
Ovoca Bio EUR 0 0 Jun/2021
Pfizer USD 60.57B 1.08B Mar/2026
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025